PHARMAnetwork magazine - last issue

Menu

Latest
Magazine
Topics
Videos
Webinars
WhitePapers
Events
About us

Linkdin
Twitter

WORLD PHARMACEUTICAL & CDMO BUSINESS NEWS

N°63 November 2024
In this issue

Approvals

6 FDA: 24 novel drug approvals in 2024 Q2 and Q3

10 EMA approvals in Q2 and Q3 2024

M&A

16 The Expected Recovery in M&A Activity in Europe has not Materialized

18 CDMO M&A Activities Remain Strong in Q2 2024

Investment

36 CRMO Strategic Investment & Growth

38 Lonza’s Continued Investments in Growth and Frontier Tehnologies to Meet the Needs of Drug Developers

40 PCI: Investing in the Future: Strategic CDMO Growth in a Dynamic Market

44 CordenPharma Invests in End-toEnd CDMO Supply Expansions Across Six Technology Platforms

50 Recipharm: Strategic Shifts and Market Megatrends in Sterile Manufacturing and Biolog

52 Unithet Pharmaceuticals: Investing to Support the Growth of our Customer

Innovation

54 For Pharmaceutical Companies, Three Steps to Value with Generative AI

Regulatory

58 Case C-237/22 of the CJEU – Clarification of the Concepts of “Significant Benefit” and “Clinical Superiority”

60 Navigating the Complex Landscape of Merger Control and Foreign Direct Investment in Life Sciences in the EU and UK

Read PHARMAnetwork magazine:

Web edition

All issues of the magazine

Apps edition

IOS and Android

MAGAZINE: Web edition

November 2024 edition - n°63 : Read...

Contact us - Advertise - Privacy policy - Term of use

© Copyright 1997 - 2021 PHARMAnetwork sarl. All rights reserved.
Reproduction in whole or in part is prohibited.

Go to Top